Neurocrine Biosciences Inc Stock Price, News & Analysis

Neurocrine Biosciences (Nasdaq: NBIX) initiated a Phase 2 randomized, double-blind, placebo-controlled study of investigational NBI-1065890 in adults with tardive dyskinesia (TD) on Jan 26, 2026. NBI-1065890 is described as a next-generation, selective VMAT2 inhibitor designed for a potentially differentiated, longer-acting profile.

The study will enroll approximately 100 adults and will assess efficacy, safety, and tolerability versus placebo. The primary efficacy endpoint is change from baseline in the AIMS dyskinesia total score (Items 1–7) at Week 8. Neurocrine notes prior FDA approvals for valbenazine in 2017 (tardive dyskinesia) and 2023 (Huntington’s chorea).

Neurocrine Biosciences (Nasdaq: NBIX) will host its fourth quarter and year-end 2025 financial results conference call and webcast on February 11, 2026. The press release will be issued at 1:00 p.m. PT / 4:00 p.m. ET, followed by the conference call at 1:30 p.m. PT / 4:30 p.m. ET. Domestic dial-in: 800-579-2543; international dial-in: 785-424-1789; conference ID: NBIX. The webcast will be available at neurocrine.com under Investors, with a replay posted about one hour after the event and archived for ~one month.

Neurocrine focuses on treatments for neurological, psychiatric, endocrine and immunological disorders and maintains a mid-to-late phase clinical pipeline.

Neurocrine Biosciences (NASDAQ: NBIX) presented head-to-head PET imaging data comparing VMAT2 target occupancy for INGREZZA (valbenazine) versus AUSTEDO XR (deutetrabenazine) at therapeutic doses on January 15, 2026. The primary analysis reported a least-squares mean VMAT2 occupancy of ~76.5% for INGREZZA versus ~38.3% for AUSTEDO XR after single doses. Estimated steady-state occupancies were 83%/92% for INGREZZA (40/80 mg) and 54%/70% for AUSTEDO XR (24/48 mg). Both drugs were generally well tolerated; findings were presented at ACNP Jan 12–15, 2026.

Neurocrine Biosciences (Nasdaq: NBIX) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. Pacific Time in San Francisco. Kyle Gano, Chief Executive Officer, will deliver the presentation.

The live webcast can be accessed via the company's Investors website at neurocrine.com. A replay will be posted approximately one hour after the event and archived for about one month.

Neurocrine is a neuroscience-focused biopharmaceutical company with FDA-approved treatments across tardive dyskinesia, Huntington's chorea, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids (collaboration with AbbVie), and a mid- to late-stage clinical pipeline.

Neurocrine Biosciences (Nasdaq: NBIX) announced that its Phase 3 KINECT-DCP study of valbenazine in pediatric and adult participants with dyskinetic cerebral palsy did not meet primary or key secondary endpoints (Dec. 22, 2025).

The 14-week, double-blind, placebo-controlled study—described as the largest trial ever completed in DCP—assessed improvement in chorea. Adverse events were reported as generally consistent with valbenazine's established safety profile. The company thanked patients, families, investigators, and site staff and said it will present full study results at an upcoming scientific meeting.

Neurocrine Biosciences (NASDAQ: NBIX) outlined a transformed R&D strategy at its 2025 R&D Day focused on neuroscience and endocrinology, aiming to deliver multiple first‑ and best‑in‑class medicines this decade. Key clinical milestones include topline Phase 3 data for osavampator and direclidine expected in 2027, additional direclidine and bipolar study readouts in 2028, and a CRF2 obesity program (NBIP-'2118) planned to enter Phase 1 in H1 2026. The company said its R&D engine targets at least four new Phase 1 and two Phase 2 programs per year and expects an approved medicine every two years by the end of the decade.

Neurocrine Biosciences (Nasdaq: NBIX) will hold its 2025 R&D Day on Tuesday, December 16, 2025 at 12:00 p.m. ET in San Diego. Management will highlight the company’s R&D transformation and its growing neuroscience pipeline and will feature a discussion with key opinion leader John Krystal, M.D. from Yale.

The event will be available via a live webcast on the company’s Investor website, with a replay and the R&D Day presentation posted approximately one hour after the event and archived for about one month.

Neurocrine Biosciences (Nasdaq: NBIX) announced publication of a peer‑reviewed narrative review in CNS Spectrums that consolidates pharmacologic, pharmacokinetic and >10 years of clinical research on two FDA‑approved VMAT2 inhibitors for tardive dyskinesia.

The review highlights a distinctive profile for INGREZZA (valbenazine), noting selective VMAT2 targeting, metabolism to a single potent metabolite, a therapeutic response at the lowest available 40 mg dose, simplified no‑titration dosing and extensive long‑term efficacy and tolerability data across diverse patient populations.

A supplemental reference guide accompanies the manuscript to support dosing, drug interaction and clinical decision considerations.

Neurocrine Biosciences (Nasdaq: NBIX) reported Phase 2 SAVITRI results showing that once-daily 1 mg osavampator produced statistically significant and clinically meaningful reductions in depression severity at Day 28 and Day 56 versus placebo in adults with major depressive disorder with inadequate response to antidepressants. The randomized 2:1:1 study enrolled 183 adults. Osavampator was generally well tolerated with no serious adverse events; common TEAEs included headache and nasopharyngitis. An exploratory exposure-response analysis supports continuing 1 mg into planned Phase 3 studies.